Kagoshima, Japan

Midori Takeda

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Daikin Industries, Ltd., Kagoshima University, Okayama University. Active years: 2021.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Midori Takeda: Innovator in Anti-Hepatoma Virus Research

Introduction

Midori Takeda is a prominent inventor based in Kagoshima, Japan. She has made significant contributions to the field of medical research, particularly in the development of therapeutic agents for hepatoma viruses. Her innovative work has the potential to impact the treatment of liver cancer.

Latest Patents

Midori Takeda holds a patent for an anti-hepatoma virus agent. This invention aims to provide a novel therapeutic agent for hepatoma viruses. Specifically, the patent relates to an anti-hepatoma virus agent that contains as an active ingredient a compound represented by a specific formula or a pharmaceutically acceptable salt thereof. This advancement is crucial in the ongoing battle against liver cancer.

Career Highlights

Throughout her career, Midori Takeda has worked with notable organizations, including Daikin Industries, Ltd. and Okayama University. Her experience in these institutions has allowed her to collaborate with leading experts in her field and contribute to groundbreaking research.

Collaborations

Midori has collaborated with esteemed colleagues such as Masanori Ikeda and Masanori Baba. These partnerships have enriched her research and expanded the impact of her innovations.

Conclusion

Midori Takeda's work in developing an anti-hepatoma virus agent showcases her dedication to advancing medical science. Her contributions are vital in the fight against liver cancer, and her innovative spirit continues to inspire future research in this critical area.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…